Taurine Attenuates Doxorubicin-Induced Toxicity on B16F10 Cells

Adv Exp Med Biol. 2017:975 Pt 2:1179-1190. doi: 10.1007/978-94-024-1079-2_94.

Abstract

This study aimed to investigate the effect of doxorubicin co-treatment with taurine on B16F10 melanoma cells. Frequently, Doxorubicin is used in the treatments of many different kinds of cancers, some of which are soft tissue sarcomas, hematological malignancies and carcinomas. However, the clinical application of doxorubicin is compromised by its severe adverse effects, including cardiotoxicity. In the present study, the efficacy of doxorubicin co-treatment with taurine was investigated. B16F10 cell viability was evaluated using MTT assays, trypan blue dye exclusion assays, and fluorescent staining technique. Apoptotic cells were detected by flow cytometry and the proteins associated with apoptosis and cellular differentiations were assessed by immunoblotting. Doxorubicin inhibited cell growth and induced cell death in B16F10 cells. Interestingly, doxorubicin co-treatment with taurine inhibited apoptosis in B16F10 cells. These results indicate that doxorubicin co-treatment with taurine attenuates doxorubicin-induced cytotoxicity and reduces ROS production in B16F10 cells.

Keywords: B16F10 cells; Doxorubicin; Reactive oxygen species.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic / toxicity*
  • Apoptosis / drug effects*
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Doxorubicin / toxicity*
  • Melanoma, Experimental
  • Mice
  • Oxidative Stress / drug effects*
  • Reactive Oxygen Species
  • Taurine / pharmacology*

Substances

  • Antibiotics, Antineoplastic
  • Reactive Oxygen Species
  • Taurine
  • Doxorubicin